Coya Therapeutics, Inc. · NASDAQ:COYA
Coya Therapeutics — Investor Presentation (March 2026)
36 slides from Coya Therapeutics's investor presentation, March 2026
Slide 1: Combating Neurodegeneration Via Treg Directed Combination Therapy
Combating Neurodegeneration Via Treg Directed Combination Therapy Investor Overview March 2026
Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers
Cautionary Note of Forward-Looking Statements and Disclaimers in this Presentation This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-lo
Slide 3: Coya Therapeutics (COYA): Investment Highlights
Coya Therapeutics (COYA): Investment Highlights Indications With High Unmet Need • ALS, Frontotemporal Dementia (FTD), Alzheimer's Disease (AD) • De-risked approach with regulatory flexibility Novel Combination Therapies • COYA 302 (ALS, FTD) and COYA 303 (AD) have differentiated approach targeting
Slide 4: Coya's Late Stage Neurodegenerative Pipeline
Coya's Late Stage Neurodegenerative Pipeline Product IND-Enabling Phase 1 Phase 2 Phase 3 Partner Dr. Reddy’s Labs COYA 302 (worldwide, Low Dose IL-2 + ALS (Amyotrophic Lateral Sclerosis) excl. Japan & CTLA4-Ig LatAm) FTD (Frontotemporal Dementia) Coya retains worldwide rights COYA 303 Alzheimer's D
Slide 5: Key Catalysts and Milestones
Key Catalysts and Milestones COYA 302 in ALS: • Complete enrollment: expected 2H 2026 ALSTARS (Phase 2) • Top-line data: expected 1Q 2027 • Management to provide periodic updates COYA 302 in FTD: • Acceptance of IND: accepted 1Q 2026 • initiate Phase 2a study: expected 2H 2026 Translational Datasets
Slide 6: Pipeline > $10B Opportunity in ALS, FTD, AD & PD
Pipeline > $10B Opportunity in ALS, FTD, AD & PD COYA 302: ALS and FTD • High unmet need ALS FTD • Orphan indications • Flexible & fast path to market • > $5Bn market Neurodegeneraive Indications with High COYA 303: Alzheimer’s Disease Unmet Medical Need Alzheimer’s Parkinson’s • One of the most com
Slide 7: LD IL-2 Combination Therapy: Pillars For Success
LD IL-2 Combination Therapy: 3 Pillars For Success The neurodegeneration field increasingly recognizes combination-based therapeutic strategies such as Coya's as a viable path forward for diseases driven by complex, multifactorial biology Differentiated Combination- Validated Science Early Clinical
Slide 8: Treg Focused Pipeline: Critical Role in Inflammation
Treg Focused Pipeline: Critical Role in Inflammation Tregs (Regulatory T Cells) By helping functional regulatory T cells (Tregs) maintain immune • Specialized immune cells that help balance, Coya combinations restrain chronic inflammation and maintain a balanced immune system limit pathways that dri
Slide 9: Treg Imbalance Leads to Neuroinflammation…
Treg Imbalance Leads to Neuroinflammation… … And neuroinflammation leads to neurodegeneration, which drives disease progression Healthy Neuron Sick Neuron Dead Neuron Loss of selective population of neurons Healthy Tregs Pro-Inflammatory Cells
Slide 10: Rebalancing Treg Leads to Improved Clinical Outcomes
Rebalancing Treg Leads to Improved Clinical Outcomes Coya combination therapies: • Restore and enhance Tregs function, numbers, and survival • Mechanistically reduces chronic neuroinflammation due to immune dysregulation • Drive improved disease outcomes in neurodegenerative and autoimmune disease S
Slide 11: COYA 302 in ALS & FTD
COYA 302 in ALS & FTD Proprietary, Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and CTLA4-Ig
Slide 12: COYA 302 in ALS and FTD
COYA 302 in ALS and FTD ALS and Frontotemporal Dementia • High unmet need • Relatively short life expectancy from time of diagnosis • Significant loss of QoL • Orphan diseases • Flexible and fast paths to regulatory approval • ALS: ~33,000 patients in U.S. (NIH) • FTD: 50,000-60,000 patients in U.S.
Slide 13: COYA 302: Combo Therapies Enhance Treg Function
COYA 302: Combo Therapies Enhance Treg Function Dysfunctional immuno-regulatory environment due to inflammation Restoring Immune Regulation via Combination Therapy • Inflammation creates a dysfunctional immuno- regulatory environment o Tregs are dysregulated and dysfunctional Dysfunctional Tregs CD8
Slide 14: COYA 302 in ALS
COYA 302 in ALS
Slide 15: Current ALS Therapies aim to slow disease progression
Current ALS Therapies aim to slow disease progression Many companies have garnered significant value by PRO-ACT ALS Database Mean (SD) Documented demonstrating Decline (ALSFRS-R) a limited` benefit of slowing the rate of ALS progression 2 3 Baseline 4 8 12 16 20 24 Weeks ALS patients average rate of
Slide 16: LD IL-2 + CTLA4-Ig IIT: Signal in Mild-to-Moderate ALS
LD IL-2 + CTLA4-Ig IIT: Signal in Mild-to-Moderate ALS ALSFRS-R improved or stabilized over 6 CTLA-4 Ig + LD IL-2 ameliorates progression months in a 48 week IST in ALS Patients Mean (±SD) ALSFRS-R Score (N=4) 48 44 33.5 33.75 32 30 40 36 ALSFRS-R Score 32 28 24 20 16 12 48-Week Treatment Follow-Up
Slide 17: LD IL-2+CTLA4 Ig: Restored Treg Suppressive Function
LD IL-2+CTLA4 Ig: Restored Treg Suppressive Function LD IL-2 + CTLA4 Ig combination is synergistic and effective ** ** ** * LD IL-2 + CTLA4-Ig * • Significantly expanded Treg suppressive function as early as week 4 ** • Maintained a significantly increased Treg function • Increased Treg numbers as e
Slide 18: COYA 302: ALSTARS Phase 2 Study in ALS Ongoing
COYA 302: ALSTARS Phase 2 Study in ALS Ongoing Key Inclusion Criteria Primary Endpoint Randomized, Double-Blind, Placebo-Controlled Change in disease • Diagnosis of sporadic or Phase 2 Study with Blinded Active Extension severity over time familial ALS measured by ALSFRS-R • ALSFR-R score ≥ 35 at 4
Slide 19: COYA 302 in FTD
COYA 302 in FTD
Slide 20: LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD
LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD Encouraging clinical data in FTD in Investigator Sponsored Study • Treg suppressive function and percentage: o Increased after first treatment o Remained elevated across 22-week treatment period Increased Treg Suppressive Function Expansion of Treg
Slide 21: LD IL-2 & CTLA-4 Ig: Signal in FTD – cont.
LD IL-2 & CTLA-4 Ig: Signal in FTD – cont. Cognitive Stability in 22-Week Investigator Sponsored Study • CDR‐FTLD, MoCA, PASS cognitive tests exhibited no cognitive decline at end of study compared with baseline Moca Scores Remains CDR-FTLD Scores Remains Unchanged Compared to Unchanged Compared to
Slide 22: COYA-302 in FTD: Phase 2a Expected 2Q 2026 Start
COYA-302 in FTD: Phase 2a Expected 2Q 2026 Start Primary Endpoint Randomized, Double-Blind, Placebo-Controlled • Safety and Phase 2a Study with Open Label Extension tolerability Key Inclusion Criteria 4 wk. 24 wk. Double Blind 24 week Open Label Clinical Efficacy • Non-Fluent Primary Screening Treat
Slide 23: COYA 301
COYA 301 Proprietary Low Dose Recombinant Human IL-2
Slide 24: LD IL-2 Monotherapy in AD: Exciting Phase I POC
LD IL-2 Monotherapy in AD: Exciting Phase I POC LD IL-2 monotherapy works in Alzheimer's • Enhanced Treg function and numbers • Stabilized cognitive decline Combination with GLP-1 receptor agonist offers: • Enhanced clinical benefit • Synergistic advantage over monotherapy • Validation of low-dose I
Slide 25: COYA 303 in Alzheimer's
COYA 303 in Alzheimer's Proprietary, Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and GLP-1 RA
Slide 26: COYA 303 in Alzheimer's Disease
COYA 303 in Alzheimer's Disease Alzheimer's Disease • High unmet need • Significant loss in QoL • >7 million patients in U.S. COYA 303 • Proprietary combination (co-administered) • Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and GLP-1 receptor agonist • IP through 2040's Strong scientific r
Slide 27: COYA in Alzheimer's: Compelling Preclinical Signal
COYA 303 in Alzheimer's: Compelling Preclinical Signal Encouraging in-vitro and in LPS mouse model • Lipopolysaccharide (LPS) mouse model is well-characterized of systemic and neuro-inflammation • COYA 303 decreased both periphery inflammation and in neuro-inflammation • Mechanistic synergy: complem
Slide 28: Leadership
Leadership • Management • Scientific Advisory Board • Board of Directors
Slide 29: Management
Management Arun Swaminathan, Fred Grossman, D.O., David Snyder Ph.D. FAPA Chief Financial Officer & Chief Executive Officer President & Chief Chief Operating Officer Medical Officer • Bristol Myers Squibb • Johnson-Johnson • DisperSol Technologies • Actinium • Sunovion • Exicure • Covance • Bristol
Slide 30: Experienced Development Team
Experienced Development Team Michelle Frazier, Ph.D. Karen King, MS Daniel Barvin, M.B.A Senior Vice President of Management and Clinical Vice President of Regulatory Affairs Operations Operations & Patient Advocacy • Revance Therapeutics • Recursion • End The Legacy: • CytomX • MacroGenics Genetic
Slide 31: Scientific Advisors Board
Scientific Advisors Board Shimon Sakaguchi, Clive Svendsen, Ph.D. Malcolm Brenner, M.D., Stanley Appel, M.D. M.D., Ph.D. Director, Cedars-Sinai Ph.D. Co-Director, Houston Member of the National Regenerative Medicine Director, Center for Cell and Methodist Neurological Institute Gene Therapy Institut
Slide 32: Board of Directors
Board of Directors Howard Berman, Ph.D. Ann Lee, Ph.D. Dov Goldstein, M.D., MBA Executive Chairman Chief Technical Officer Chief Financial Officer of the Board Prime Medicine BioAge Labs Wilbur Ross Anabella Villalobos, Ph.D. Dieter Weinand Former U.S. Secretary of Former Head of Biotherapeutics For
Slide 33: Appendix
THERAPEUTICS Appendix
Slide 34: IL-2 is Essential in Treg Biology
IL-2 is Essential in Treg Biology IL-2 Romano et al., Frontiers in Neurology, 31 January 2019 doi: 10.3389/fimmu.2019.00043
Slide 35: LD IL-2 + CTLA4-Ig Investigator Initiated Trial
LD IL-2 + CTLA4-Ig Investigator Initiated Trial Open-Label, Single-Arm PoC Clinical Study in ALS Patients (N=4) Screening Treatment Period Follow-Up 20 weeks LD IL-2 + CTLA4-Ig was administered via 8 weeks subcutaneous injection over 48 weeks Screening Assessments Treatment Period Assessments Post-T
Slide 36: LD IL-2 + CTLA4-Ig Investigator Initiated Trial – cont.
LD IL-2 + CTLA4-Ig Investigator Initiated Trial – cont. Baseline Characteristics ALS Progression Age Respiratory Respiratory Sex Type Onset Prior to Baseline (years) Status Support (ALSFRS-R score) No Respiratory Patient 1 47 Female Familial Limb -1.6 points / month None Insufficiency Respiratory No
Coya Therapeutics — Investor Presentation (March 2026) on 6ix